Solara Active Pharma Sciences Ltd. · NSE:SOLARA
Solara Active Pharma Sciences — Q4 FY2019 Earnings Presentation
14 slides from Solara Active Pharma Sciences's earnings presentation, May 16, 2019
Slide 1: Solara Active Pharma Sciences Q4 FY19 Results
RESPECT INTEGRITY TRANSPARENCY EFFICIENCY MAY 16, 2019
Slide 2: Safe Harbour
Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 3: Index
Index 01 PERFORMANCE HIGHLIGHTS 02 BUSINESS UPDATES 03 CORPORATE UPDATES 04 FY20 OUTLOOK 3
Slide 4: FY19 delivers a consistent upward performance
FY19 delivers a consistent upward performance Revenues Reported EBITDA 10,367 13,991 1,458 2,316 CEO’S PERSPECTIVE “FY19 was essentially the first full year of operations for Solara as an independent entity and we are delighted to have delivered a stellar growth both in revenues and profitability. 3
Slide 5: Steady >20% operating margins in Q4FY19
Steady >20% operating margins in Q4FY19 QOQ MOVEMENT HIGHLIGHTS Particulars Q4 FY19 Q3 FY19 Change • Operating margins were steady at ~ 21% Revenue 3,919 3,601 9% Operating EBITDA 806 757 6% • Operating EBITDA improvement on account of new product Operating EBITDA Margins 21% 21% launches & growth i
Slide 6: Regulated markets now contribute 76% to the total revenues
Regulated markets now contribute 76% to the total revenues FY19 GEOGRAPHY MIX 1 Particulars H2FY19 H2FY18 YoY% FY19 % Cont. KEY UPDATES Regulated Markets 5,761 3,746 54% 10,633 76% Yearly Review -North America 2,789 2,040 37% 5,177 37% • The regulated markets grew 54% in H2FY19 largely driven by -EU
Slide 7: Over 550bps improvement in margins over 8 quarters
Over 550bps improvement in margins over 8 quarters SIGNIFICANT GROWTH IN QUARTERLY REVENUES OPERATING MARGIN IMPROVEMENT 1000 0.5 3,919 806 3,601 757 3,437 800 669 0.4 3,033 631 2,798 2,871 2,338 2,361 600 451 492 0.3 380 400 0.2 235 21% 21% 19% 21% 200 16% 16% 17% 0.1 10% 0 0 Q1FY18 Q2FY18 Q3FY18 Q
Slide 8: Strengthened balance sheet with improved key ratios
Strengthened balance sheet with improved key ratios KEY BALANCE SHEET ITEMS NET DEBT/EQUITY (X) NET DEBT/EBITDA (X) Balance sheet items Mar'18 Mar'19 1.5 4.0 Shareholders' funds 7,640 9,559 0.8 2.0 Less: Goodwill -3,634 -3,587 Networth 4,006 5,972 FY18 FY19 FY18 FY19 Term Loan 3,026 3,236 Working Ca
Slide 9: Board and Corporate Updates
Board and Corporate Updates Dividend Board Induction Others • The board of directors have • Ankur Thadani, Principal at TPG Growth, • Pursuant to shareholders approval at the recommended a dividend of ₹5 per share has been appointed as non-executive and extraordinary general meeting held on (50% div
Slide 10: FY20 Outlook- Continued growth through efficiencies
FY20 Outlook- Continued growth through efficiencies Efficiencies in Business Operations Focused R&D Strategies • Proactive cost improvement programs to stay competitive • Focus on developing IP to create entry barrier for and for contributing to sustainable growth & margin competition and build stro
Slide 11: Our Upcoming Greenfield site at Vizag, India
Our Upcoming Greenfield site at Vizag, India Investments Focus Capability Project status • Phase I Investment of • Cater to future growth of • Dedicated and Multi • Phase-I construction ₹2,500m over a period of Solara Purpose blocks for Large planned to be completed in two years Volume and Mid-Small
Slide 12: Solara Active Pharma at a glance
Solara Active Pharma at a glance API only business model with large scale infrastructure, wide products and established customer relationships Capabilities Research Complex chemistry capabilities Pipeline of 20+ products under including handling of catalytic different stages of development hydrogena
Slide 13: Well on its path to become a leading global pure-play API company
Well on its path to become a leading global pure-play API company Business Continuity Portfolio of new products and new customers to augment current base and enable steady growth Worldwide Presence Well on its path to become a Established strongholds in key regulated markets and growth territories l
Slide 14: Registered Office
REGISTERED OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703. Tel.: +91 22 2789 2924 Fax No. +91 22 2789 2942 Email: [email protected] Website: www.solara.co.in CIN: L24230MH2017PLC291636 CORPORATE OFFICE 3rd & 4th Floor, Batra Centre, No.28, Sardar Patel Road, Guindy, Chennai - 60
Solara Active Pharma Sciences — Q4 FY2019 Earnings Presentation on 6ix